<DOC>
	<DOCNO>NCT00006708</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . It yet know whether combination chemotherapy effective without rituximab non-Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy without rituximab treat patient relapsed refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>S0019 Combination Chemotherapy With Without Rituximab Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare progression-free overall survival patient relapse refractory , CD20 expressing , aggressive , B-cell non-Hodgkin 's lymphoma treat ifosfamide , carboplatin , etoposide without rituximab . II . Compare unconfirmed response rate patient treat regimen . III . Determine toxicity ifosfamide , carboplatin , etoposide rituximab patient . OUTLINE : This randomize study . Patients stratify accord histology ( large B-cell v ) risk group ( low/low-intermediate v high-intermediate/high ) . Patients randomize one two treatment arm . Arm I : Patients receive etoposide IV 1 hour day 1-3 , carboplatin IV 1 hour day 2 , ifosfamide IV continuously 24 hour day 2 , filgrastim ( G-CSF ) subcutaneously ( SC ) day 5-12 . Treatment continue every 3 week 3 course absence disease progression unacceptable toxicity . Arm II : Patients receive rituximab IV day 1 , etoposide IV 1 hour day 2-4 , carboplatin IV 1 hour day 3 , ifosfamide IV continuously 24 hour day 3 , G-CSF SC day 6-13 . Patients also receive rituximab IV day 8 course 1 . Treatment continue every 3 week 3 course absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year , every 6 month 2 year , annually 5 year . PROJECTED ACCRUAL : A total 376 patient ( 188 per arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven aggressive Bcell nonHodgkin 's lymphoma fail prior combination chemotherapy anthracyclinecontaining regimen Eligible histology : Diffuse large cell Small noncleaved cell/Burkitt 's lymphoma No lymphoblastic mantle cell lymphoma First relapse primary refractory disease Ineligible refuse treatment salvage chemotherapy follow highdose therapy autologous stem cell rescue Documented CD20 antigen expression Measurable disease No clinical evidence CNS involvement lymphoma PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Other : HIV negative Not pregnant nurse Fertile patient must use effective contraception No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior rituximab Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : Recovered toxic effect prior therapy No concurrent therapy unless disease progression occur</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
</DOC>